Sanofi Ventures reinvested in the vaccine developer through a series B round that followed a $51m series A 18 months ago.
US-based vaccine developer Icosavax completed a $100m series B round yesterday that included pharmaceutical firm Sanofi’s strategic investment arm, Sanofi Ventures. Investment manager RA Capital Management led the round, which was also backed by fellow new investors Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant Asset Management, Omega Funds, Open Philanthropy and Surveyor Capital.…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
